

**LAHIVE  
&  
COCKFIELD**  
LLP

COUNSELLORS AT LAW  
28 STATE STREET  
BOSTON, MASSACHUSETTS 02109-1784  
TELEPHONE (617) 227-7400  
FAX (617) 742-4214  
lc@lahive.com

JOHN A. LAHIVE, JR. (1928-1997)  
THOMAS V. SMURZYNSKI  
RALPH A. LOREN  
GIULIO A. DECONTI, JR.  
ANN LAMPORT HAMMITTE  
ELIZABETH A. HANLEY  
AMY BAKER MANDRAGOURAS  
ANTHONY A. LAURENTANO  
KEVIN J. CANNING  
JANE E. REMILLARD  
DEANN FORAN SMITH  
PETER C. LAURO  
DEBRA J. MILASINIC, Ph.D.  
DAVID J. RIKKERS  
DAVID R. BURNS  
JOHN S. CURRAN  
SEAN D. DETWEILER  
MEGAN E. WILLIAMS, Ph.D.

LISA M. DROCCO  
MATHAWAY P. RUSSELL \*  
MARIA LACCOTRIPE ZACHARAKIS, Ph.D.  
VINCENT P. LOCCISANO  
MERIDETH C. ARNOLD  
DANIELLE L. MERRITT  
EUNHOON LEE \*\*

SENIOR COUNSEL  
JAMES E. COCKFIELD

OF COUNSEL  
JEREMIAH LYNCH  
WILLIAM A. SCOFIELD, JR.  
SIBLEY P. REPPERT  
JEANNE M. DIGIORGIO  
CYNTHIA L. KANIK, Ph.D.

PATENT AGENTS  
THEODORE R. WEST  
SMAYNE Y. HUFF, Ph.D.  
CYNTHIA M. SOROS  
PETER W. DINI, Ph.D.  
JONATHAN M. SPARKS, Ph.D.

TECHNICAL SPECIALISTS  
CATHERINE M. BISHOP  
JACOB G. WEINTRAUB  
CRISTIN E. HOWLEY, Ph.D.  
JILL ANN MELLO, Ph.D.

\* Admitted in TX only  
\*\* Admitted in CT only

## Facsimile Cover Sheet

**FAX RECEIVED**

MAR 13 2003

**GROUP 1600**

**To:** Examiner Jeffrey E. Russel  
**Company:** U.S. Patent and Trademark Office  
**Location:** Washington, D.C.  
**Phone:** 703-308-3975  
**Fax:** 703-305-3014

**From:** Maria Laccotripe Zacharakis  
**Phone:** (617) 227-7400  
**Fax:** (617) 742-4214  
**Case No.:** PPI-064  
**USSN 09/781,133**

**OFFICIAL**

**Date:** March 12, 2003  
**Sent By:** MCL/kat  
**Pages including this cover page:** 35

**Message:** Please ENTER AND DELIVER to Examiner Jeffrey E. Russel at Group Art Unit 1654.

The documents transmitted by this facsimile are intended for the use of the individual or the entity to which it is addressed and may contain information that is privileged, confidential and exempt from disclosure under applicable law. If the reader of the message is not the intended recipient, or the employee or agent responsible for delivering this document to the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please notify us immediately by telephone and return the original facsimile to us at the above address via the U.S. Postal Service. Thank you.

In re the application of Neil J. Hayward *et al.*Case Docket No. PPI-064

Serial No. 09/781,133

Filed: February 9, 2001

For: METHODS FOR ENHANCING THE BIOAVAILABILITY OF A DRUG

COMMISSIONER FOR PATENTS  
Washington, D.C. 20231

Sir:

Transmitted herewith for filing in connection with the above-identified application are the following:

- ☒ Amendment and Response to Office Action (including Appendices A-C);  
☒ Request for One Month Extension of Time (in duplicate); and  
☒ Statement of Limited Recognition Under 37 CFR §10.9(b).

The fee has been calculated as shown below:

|   | (Col. 1)<br>CLAIMS REMAINING<br>AFTER AMENDMENT |       | (Col. 2)<br>HIGHEST NO<br>PREVIOUSLY PAID<br>FOR | (Col. 3)<br>PRESENT<br>EXTRA |
|---|---|-------|--|------------------------------|
| TOTAL   | 9   | MINUS | 05   | = 0                          |
| INDEP   | 1   | MINUS | 14   | = 0                          |
| <input type="checkbox"/> FIRST PRESENTATION OF MULTIPLE DEP CLAIM |   |       |  |                              |

| SMALL ENTITY |                  |
|--------------|------------------|
| RATE         | ADDIT FEE        |
| 1 9 -        | \$0.00           |
| 1 42 -       | \$0.00           |
| 1 140 -      | \$0.00           |
| TOTAL        | ADDIT FEE \$0.00 |

| OTHER THAN A<br>SMALL ENTITY |                  |
|------------------------------|------------------|
| RATE                         | ADDIT FEE        |
| 1 18 -                       | \$0.00           |
| 1 84 -                       | \$0.00           |
| 1 280 -                      | \$0.00           |
| TOTAL                        | ADDIT FEE \$0.00 |

- If the entry in Col 1 is less than the entry in Col. 2, write "0" in Col. 3  
 - If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, write "20" in this space  
 - If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, write "3" in this space

The "Highest Number Previously Paid For" (Total or Independent) is the highest number found from the equivalent box in Col. 1 of a prior amendment or the number of claims originally filed.

- ☒ The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 12-0080. A duplicate copy of this sheet is enclosed.  
☒ Any filing fees under 37 CFR 1.16 for the presentation of extra claims.  
☒ Any patent application processing fees under 37 CFR 1.17.  
☒ Please charge any additional fees or credit any overpayments associated with this communication to our Deposit Account No. 12-0080. A duplicate copy of this sheet is enclosed. Applicants request any extensions of time necessary to respond.

## CERTIFICATE OF FACSIMILE TRANSMISSION

I hereby certify that this correspondence is being facsimile transmitted to: Commissioner for Patents, Washington, D.C. 20231, on the date set forth below.

March 12, 2003

Date

*Maria Laccotripe*  
 Maria Laccotripe Zacharakis, Ph.D.  
 Limited Recognition Under 37 C.F.R. 10.9(b)

LAHIVE & COCKFIELD, LLP  
 Attorneys at Law

By *Maria Laccotripe*  
 Maria Laccotripe Zacharakis, Ph.D.  
 Limited Recognition Under 37 C.F.R. 10.9(b)  
 Attorney for Applicants  
 28 State Street  
 Boston, MA 02109  
 (617) 227-7400  
 Telecopier (617) 742-4214

Date: March 12, 2003


**BEFORE THE OFFICE OF ENROLLMENT AND DISCIPLINE  
UNITED STATE PATENT AND TRADEMARK OFFICE**

**LIMITED RECOGNITION UNDER 37 CFR § 10.9(b)**

Maria C. Laccotripe Zacharakis is hereby given limited recognition under 37 CFR §10.9(b) as an employee of Lahive & Cockfield, LLP, to prepare and prosecute patent applications where the patent applicant is the client of Lahive & Cockfield, LLP, and the attorney or agent of record in the applications is a registered practitioner who is a member of the Lahive & Cockfield, LLP. This limited recognition shall expire on the date appearing below, or when whichever of the following events first occurs prior to the date appearing below: (i) Maria C. Laccotripe Zacharakis ceases to lawfully reside in the United States, (ii) Maria C. Laccotripe Zacharakis' employment with Lahive & Cockfield, LLP ceases or is terminated, or (iii) Maria C. Laccotripe Zacharakis ceases to remain or reside in the United States on an H-1 visa.

This document constitutes proof of such recognition. The original of this document is on file in the Office of Enrollment and Discipline of the U.S. Patent and Trademark Office.

**Expires: August 5, 2003**

  
Harry I. Moatz  
Director of Enrollment and Discipline

# 11/a  
Dmt  
3-25-03

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of: Neil J. Hayward *et al.*

Serial No.: 09/781,133

Filed: February 9, 2001

FOR: "Methods for Enhancing the Bioavailability of  
a Drug"

Attorney Docket No.: PPI-064


Group Art Unit: 1654

Examiner: J. E. Russel

Commissioner of Patents  
Washington, D.C. 20231Certificate of Facsimile TransmissionI hereby certify that this correspondence is being facsimile transmitted to the  
Commissioner for Patents, Washington, D.C. 20231 on the date set forth below.March 12, 2002

Date of Signature

By:

  
Maria Laccotripe Zacharakis, Ph.D.

Attorney for Applicants

Limited Recognition Under 37 C.F.R. §10.9(b)

AMENDMENT AND RESPONSE TO OFFICE ACTION

Dear Sir,

This communication is submitted in response to the Office Action dated November 12, 2002 (Paper No. 9) which issued in the above referenced application. A separate petition for the appropriate extension of time in which to respond is submitted herewith. Responsive to the office action, please amend the above identified application as follows.

In the specification:

Please replace the paragraph at page 3, lines 22-27, with the following re-written paragraph:

-- In a preferred embodiment, the drug whose bioavailability is enhanced, inhibits aggregation of natural  $\beta$ -amyloid peptide. In other preferred embodiments, the drug is an

Q1